Sionna Therapeutics (NASDAQ:SION) Shares Down 14.6% on Insider Selling

Sionna Therapeutics, Inc. (NASDAQ:SION)’s stock price was down 14.6% on Thursday after an insider sold shares in the company. The company traded as low as $34.30 and last traded at $35.27. Approximately 269,413 shares were traded during mid-day trading, a decline of 11% from the average daily volume of 304,275 shares. The stock had previously closed at $41.31.

Specifically, Director Peter A. Thompson sold 29,063 shares of Sionna Therapeutics stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $44.58, for a total value of $1,295,628.54. Following the sale, the director owned 3,530,702 shares of the company’s stock, valued at $157,398,695.16. This trade represents a 0.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Peter A. Thompson sold 1,890 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $44.57, for a total value of $84,237.30. Following the transaction, the director directly owned 3,559,765 shares of the company’s stock, valued at $158,658,726.05. This represents a 0.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In related news, Director Orbimed Advisors Llc sold 29,063 shares of Sionna Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $44.58, for a total value of $1,295,628.54. Following the sale, the director owned 3,530,702 shares of the company’s stock, valued at approximately $157,398,695.16. This trade represents a 0.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Wall Street Analysts Forecast Growth

SION has been the subject of a number of recent research reports. Royal Bank Of Canada reaffirmed an “underperform” rating and set a $24.00 price target on shares of Sionna Therapeutics in a research report on Monday, December 1st. Wall Street Zen upgraded shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Lifesci Capital started coverage on shares of Sionna Therapeutics in a research report on Tuesday, December 23rd. They issued an “outperform” rating and a $60.00 target price for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. Finally, Raymond James Financial restated a “strong-buy” rating and set a $53.00 price objective on shares of Sionna Therapeutics in a research note on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $45.43.

Key Stories Impacting Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: Analyst consensus and price targets provide upside context — brokers’ average target (~$45.43) and several buy/strong‑buy reports give the stock valuation support versus current levels, suggesting analysts expect further recovery over time. Read More.
• Neutral Sentiment: Upcoming investor event could be a catalyst — management will present at the Guggenheim Emerging Outlook: Biotech Summit on Feb. 11; the presentation may supply pipeline updates or Q&A that could move the stock depending on tone and new details. Read More.
• Negative Sentiment: Insider and institutional selling produced near‑term downward pressure — Director Peter A. Thompson and Orbimed Advisors LLC disclosed sales of 29,063 shares (plus an additional 1,890-share trim) at ~ $44.57–$44.58. Although the sales represent small percentages of large holdings, they add liquidity and can prompt stop‑loss or momentum selling around those price levels. Read More. Read More.

Sionna Therapeutics Stock Down 14.7%

The business’s 50 day simple moving average is $41.23 and its 200 day simple moving average is $32.82. The stock has a market cap of $1.57 billion and a price-to-earnings ratio of -7.24.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Hedge Funds Weigh In On Sionna Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Prudential Financial Inc. lifted its position in shares of Sionna Therapeutics by 114.6% in the second quarter. Prudential Financial Inc. now owns 135,185 shares of the company’s stock valued at $2,345,000 after buying an additional 72,185 shares during the last quarter. Braidwell LP acquired a new position in shares of Sionna Therapeutics during the 2nd quarter worth approximately $18,770,000. Bosun Asset Management LLC bought a new stake in Sionna Therapeutics in the 2nd quarter valued at $295,000. Aberdeen Group plc lifted its holdings in Sionna Therapeutics by 27.4% during the 2nd quarter. Aberdeen Group plc now owns 950,547 shares of the company’s stock valued at $16,492,000 after purchasing an additional 204,583 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Sionna Therapeutics by 2.4% during the second quarter. JPMorgan Chase & Co. now owns 2,221,188 shares of the company’s stock worth $38,538,000 after purchasing an additional 51,589 shares during the period.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.